Weiguo Su

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer

Jin Li, Shukui Qin, Rui‐Hua Xu et al. · JAMA · 2018 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17

Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study

Shun Lü, Jian Fang, Xingya Li et al. · The Lancet Respiratory Medicine · 2021 · 204 citations

Medicine, Oncology, Pharmacology +11

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Zhiwei Zhou et al. · The Lancet Oncology · 2020 · 190 citations

Medicine, Endocrinology, Oncology +8

Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Jianming Xu, Lin Shen, Chunmei Bai et al. · The Lancet Oncology · 2020 · 189 citations

Medicine, Oncology, Pharmacology +11

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Qiaoling Sun, Jinghong Zhou, Zheng Zhang et al. · Cancer Biology & Therapy · 2014 · 153 citations · Full text

Medicine, Oncology, Pharmacology +13